公开(公告)号：US20240358670A1

公开(公告)日：2024-10-31

申请号：US18766386

申请日：2024-07-08

Applicant: Viotika Life Sciences Inc.

Inventor： Pavel Dibrov ,  Elena Dibrov ,  Grant Pierce

IPC: A61K31/341 ,  A61K31/16 ,  A61K31/365 ,  A61P31/04 ,  C07D307/66 ,  C07D309/30 ,  C07F9/655

CPC classification number: A61K31/341 ,  A61K31/16 ,  A61K31/365 ,  A61P31/04 ,  C07D307/66 ,  C07D309/30 ,  C07F9/655 ,  C07F9/65515 ,  A61K2300/00 ,  Y02A50/30

Abstract: An antibiotic compound of formula (I):




or a salt or stereoisomer thereof; wherein R1-R3 and R5-R6 are independently selected from H or a C1-C5 alkyl group or a C1-C5 substituted alkyl group; R4 is a C1-C5 alkyl group or a C1-C5 substituted alkyl group; X1-X2 are independently selected from the group consisting of ═O, H, and OH; Y is an acyclic hydrocarbon chain of 2 to 20 carbon atoms; and Z is CH3. Also disclosed are methods of treating a bacterial disease including administering an effective amount of the compound to a subject in need thereof, wherein the bacterial disease is caused by a gram-negative bacteria.

公开(公告)号：US12128098B2

公开(公告)日：2024-10-29

申请号：US17160776

申请日：2021-01-28

Applicant: Squarex, LLC

Inventor： Hugh McTavish

IPC: A61K39/245 ,  A61K9/00 ,  A61K31/04 ,  A61K31/122 ,  A61K31/215 ,  A61K35/763 ,  A61K39/12 ,  A61K39/165 ,  C07K14/035 ,  G01N33/571 ,  A61K39/00

CPC classification number: A61K39/245 ,  A61K9/0014 ,  A61K9/0021 ,  A61K31/04 ,  A61K31/122 ,  A61K31/215 ,  A61K35/763 ,  A61K39/12 ,  A61K39/165 ,  C07K14/035 ,  G01N33/571 ,  A61K2039/54 ,  A61K2039/545 ,  A61K2039/55511 ,  C12N2710/16611 ,  A61K31/122 ,  A61K2300/00 ,  A61K31/04 ,  A61K2300/00 ,  A61K31/215 ,  A61K2300/00

Abstract: A method is presented for treating herpes simplex virus (HSV) infection comprising: (a) locally administering a substance that induces a delayed type hypersensitivity (DTH) response to a patient at a site other than at the site of an HSV lesion to induce a DTH response during one or more outbreaks of the HSV infection. The method reduces the number of HSV outbreaks in persons experiencing outbreaks.

公开(公告)号：US12128075B2

公开(公告)日：2024-10-29

申请号：US17303946

申请日：2021-06-10

Applicant: California Institute of Technology

Inventor： Elaine Hsiao ,  Sara McBride ,  Sarkis K. Mazmanian ,  Paul H. Patterson

IPC: A61K35/744 ,  A61K35/74 ,  A61K35/00

CPC classification number: A61K35/744 ,  A61K35/74 ,  A61K2035/115 ,  Y02A50/30 ,  A61K35/74 ,  A61K2300/00 ,  A61K35/744 ,  A61K2300/00

Abstract: Some embodiments include bacterial species for use in treatment of one or more autism spectrum disorder (ASD), and/or schizophrenia symptoms in a subject in need thereof. The bacterial species can include Bacteroides (e.g., B. fragilis, B. thetaiotaomicron, and/or B. vulgatus), and/or Enterococcus (e.g., E. faecalis, E. faecium, E. hirae, E. avium, E. durans, E. gallinarum, or E. casseliflavus). Upon treatment, one or more ASD-related behaviors can be improved in the subject.

公开(公告)号：US12128048B2

公开(公告)日：2024-10-29

申请号：US17713472

申请日：2022-04-05

Applicant: Mirati Therapeutics, Inc.

Inventor： Lars Daniel Engstrom ,  Peter Olson ,  James Gail Christensen

IPC: A61K31/519 ,  A61K31/416 ,  A61K31/502 ,  A61K31/517 ,  A61P35/00

CPC classification number: A61K31/519 ,  A61K31/416 ,  A61K31/502 ,  A61K31/517 ,  A61P35/00 ,  A61K31/519 ,  A61K2300/00 ,  A61K31/517 ,  A61K2300/00 ,  A61K31/502 ,  A61K2300/00

Abstract: This disclosure relates to methods of treating cancer. This disclosure further relates to treating cancer in a subject with compounds that are inhibitors of PRMT5, particularly in combination with KRASG12C inhibitors.

公开(公告)号：US12121546B2

公开(公告)日：2024-10-22

申请号：US17197714

申请日：2021-03-10

Applicant: Noveome Biotherapeutics, Inc.

Inventor： Larry R. Brown ,  Howard C. Wessel

IPC: A61K38/18 ,  A61K35/50 ,  A61K38/19 ,  A61K38/57

CPC classification number: A61K35/50 ,  A61K38/18 ,  A61K38/1858 ,  A61K38/1866 ,  A61K38/1891 ,  A61K38/19 ,  A61K38/191 ,  A61K38/57 ,  A61K38/1858 ,  A61K2300/00 ,  A61K38/1866 ,  A61K2300/00 ,  A61K38/1891 ,  A61K2300/00 ,  A61K38/57 ,  A61K2300/00

Abstract: The invention is directed to methods for the treatment of diseases and conditions caused by increased vascular permeability. The invention is also directed to methods for returning vascular permeability that is a symptom of a disease or condition to a homeostatic state. Specifically, the invention is directed to methods for the treatment of diseases and conditions caused by increased vascular permeability or returning vascular permeability that is a symptom of a disease or condition to a homeostatic state by administering to a subject suffering from such diseases and conditions and symptoms novel cellular factor-containing solution compositions (referred to herein as “CFS” compositions), including novel sustained-release cellular factor-containing solution compositions (referred to herein as “SR-CFS” compositions).

公开(公告)号：US12121536B2

公开(公告)日：2024-10-22

申请号：US17646805

申请日：2022-01-03

Applicant: Galleon Labs LLC

Inventor： Gary S. Hahn ,  Siva Gudi

IPC: A61K33/00 ,  A61K9/00 ,  A61K31/19 ,  A61K31/198 ,  A61K31/22 ,  A61K33/14 ,  A61K47/32 ,  A61K47/54 ,  A61K31/455 ,  A61K33/18 ,  A61K33/38 ,  A61K45/06

CPC classification number: A61K33/00 ,  A61K9/0014 ,  A61K31/19 ,  A61K31/198 ,  A61K31/22 ,  A61K33/14 ,  A61K47/32 ,  A61K47/542 ,  A61K9/0053 ,  A61K31/455 ,  A61K33/18 ,  A61K33/38 ,  A61K45/06 ,  A61K33/14 ,  A61K2300/00 ,  A61K31/22 ,  A61K2300/00 ,  A61K31/198 ,  A61K2300/00

Abstract: Therapeutically-active compositions and formulations for treating pain, pruritus, irritation, inflammation, and tissue damage due to the irritation and inflammation, and therapeutically-active compositions and formulations for wound management, including wounds that are at high risk for infection. Strontium and beta hydroxybutyrate based compositions and formulations which can be topically applied.

公开(公告)号：US12115255B2

公开(公告)日：2024-10-15

申请号：US18418030

申请日：2024-01-19

Applicant: Heron Therapeutics, Inc.

Inventor： Thomas B. Ottoboni ,  Han Han

IPC: A61K31/5377 ,  A61K9/00 ,  A61K9/107 ,  A61K31/43 ,  A61K31/435 ,  A61K31/496 ,  A61K31/573 ,  A61K47/10 ,  A61K47/24 ,  A61K47/44 ,  G06F16/903 ,  G06F16/9038 ,  G06N20/00

CPC classification number: A61K9/1075 ,  A61K9/0019 ,  A61K31/43 ,  A61K31/435 ,  A61K31/496 ,  A61K31/5377 ,  A61K31/573 ,  A61K47/10 ,  A61K47/24 ,  A61K47/44 ,  G06F16/90344 ,  G06F16/9038 ,  G06N20/00 ,  A61K31/5377 ,  A61K2300/00 ,  A61K31/573 ,  A61K2300/00 ,  A61K31/435 ,  A61K2300/00 ,  A61K31/496 ,  A61K2300/00

Abstract: Disclosed herein are novel pharmaceutical formulations of a neurokinin-1 (NK-1) receptor antagonist suitable for parenteral administration including intravenous administration. Also included are formulations including both the NK-1 receptor antagonist and dexamethasone sodium phosphate. The pharmaceutical formulations are stable oil-in-water emulsions for non-oral treatment of emesis and are particularly useful for treatment of subjects undergoing highly emetogenic cancer chemotherapy.

公开(公告)号：US12115254B2

公开(公告)日：2024-10-15

申请号：US18408486

申请日：2024-01-09

Applicant: Heron Therapeutics, Inc.

Inventor： Thomas B. Ottoboni ,  Han Han

IPC: A61K9/107 ,  A61K9/00 ,  A61K31/43 ,  A61K31/435 ,  A61K31/496 ,  A61K31/5377 ,  A61K31/573 ,  A61K47/10 ,  A61K47/24 ,  A61K47/44 ,  G06F16/903 ,  G06F16/9038 ,  G06N20/00

CPC classification number: A61K9/1075 ,  A61K9/0019 ,  A61K31/43 ,  A61K31/435 ,  A61K31/496 ,  A61K31/5377 ,  A61K31/573 ,  A61K47/10 ,  A61K47/24 ,  A61K47/44 ,  G06F16/90344 ,  G06F16/9038 ,  G06N20/00 ,  A61K31/5377 ,  A61K2300/00 ,  A61K31/573 ,  A61K2300/00 ,  A61K31/435 ,  A61K2300/00 ,  A61K31/496 ,  A61K2300/00

Abstract: Disclosed herein are novel pharmaceutical formulations of a neurokinin-1 (NK-1) receptor antagonist suitable for parenteral administration including intravenous administration. Also included are formulations including both the NK-1 receptor antagonist and dexamethasone sodium phosphate. The pharmaceutical formulations are stable oil-in-water emulsions for non-oral treatment of emesis and are particularly useful for treatment of subjects undergoing highly emetogenic cancer chemotherapy.

公开(公告)号：US12115179B2

公开(公告)日：2024-10-15

申请号：US18320462

申请日：2023-05-19

Applicant: Boehringer Ingelheim International GmbH

Inventor： Peter Eickelmann ,  Michael Mark ,  Leo John Seman ,  Leo Thomas ,  Uli Christian Broedl ,  Rolf Grempler

IPC: A61K31/7048 ,  A61K31/00 ,  A61K31/155 ,  A61K31/198 ,  A61K31/341 ,  A61K31/351 ,  A61K31/39 ,  A61K31/403 ,  A61K31/4439 ,  A61K31/522 ,  A61K31/70 ,  A61K31/7004 ,  A61K31/7008 ,  A61K45/06

CPC classification number: A61K31/7048 ,  A61K31/00 ,  A61K31/155 ,  A61K31/198 ,  A61K31/341 ,  A61K31/351 ,  A61K31/39 ,  A61K31/403 ,  A61K31/4439 ,  A61K31/522 ,  A61K31/70 ,  A61K31/7004 ,  A61K31/7008 ,  A61K45/06 ,  A61K31/00 ,  A61K2300/00 ,  A61K31/155 ,  A61K2300/00 ,  A61K31/198 ,  A61K2300/00 ,  A61K31/341 ,  A61K2300/00 ,  A61K31/351 ,  A61K2300/00 ,  A61K31/39 ,  A61K2300/00 ,  A61K31/403 ,  A61K2300/00 ,  A61K31/4439 ,  A61K2300/00 ,  A61K31/70 ,  A61K2300/00 ,  A61K31/7004 ,  A61K2300/00 ,  A61K31/7008 ,  A61K2300/00

Abstract: The invention relates to a pharmaceutical composition comprising an SGLT2 inhibitor, a DPPIV inhibitor and a third antidiabetic agent which is suitable in the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance and hyperglycemia. In addition the present invention relates to methods for preventing or treating of metabolic disorders and related conditions.

公开(公告)号：US12109219B2

公开(公告)日：2024-10-08

申请号：US16849216

申请日：2020-04-15

Applicant: Arena Pharmaceuticals, Inc.

Inventor： Jayant Thatte ,  Anthony C. Blackburn ,  Sangdon Han ,  Robert M. Jones ,  Jae-Kyu Jung ,  Antonio Garrido Montalban ,  Biman B. Pal ,  Jaimie Karyn Rueter ,  Sonja Strah-Pleynet ,  Lars Thoresen ,  Yifeng Xiong ,  Dawei Yue ,  Xiuwen Zhu

IPC: A61K31/675 ,  A61K31/416 ,  A61K31/4439 ,  A61K31/497 ,  A61K45/06

CPC classification number: A61K31/675 ,  A61K31/416 ,  A61K31/4439 ,  A61K31/497 ,  A61K45/06 ,  A61K31/416 ,  A61K2300/00

Abstract: Provided are certain methods useful in the treatment of cancer comprising administering a compound of Formula Ia and pharmaceutical compositions thereof that modulate the activity of the cannabinoid CB2 receptor;